www.BRIDGenomics.com

Bridging Gaps in Genomics

Professional Services for Advanced Molecular Testing

Maximize Your Return on Investment

BRIDGenomics helps clinical organizations develop and commercialize genomic testing and maximize ROI.

Our highly experienced team can reduce your time to assay commercialization by 75% and help you quickly grow revenue.

We’ve done this before and we can do it for you.

Quest Diagnostics

LabPMM Invivoscribe

Cancer Genetics Inc

BioGx

Geneuity

MPLN

Assay Commercialization

Typical NGS Assay Commercialization Timeline: 9 -18 monthsTypical NGS Assay Commercialization Cost: $500k - $750k

These estimates exclude the cost of equipment

We routinely commercialize NGS-based LDTs in less than 3 months

BRIDGenomics average timeline includes: build out and staffing of lab space, as well as commercialization of testing including state inspection/accreditation in under 90 days.

Experience Empowers

Our Team’s Selected Publications

This is why we routinely commercialize NGS-based LDTs in less than 3 months

Products Developed and Commercialized Projects supporting multiple sectors

Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory. 2015. PLoS ONE 10(8): e0136419. doi:10.1371/journal.pone.0136419

A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients. 2012. PLoS ONE 7(9): e46334. doi:10.1371/journal.pone.0046334

CLSI. Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicine; Approved Guideline – Second Edition. CLSI document MM09-A2. Wayne, PA. Clinical and Laboratory Standards Institute; 2014.

Depend on our Deep Domain Knowledge

More than 25 years of experience ▪ System, Product, and Assay development and validation▪ High-Complexity Molecular Testing▪ Emerging Technology Market Assessment▪ Implementation of New Technologies ▪ PI on Clinical Studies for Pharma▪ Invited Speaker▪ Significant Patent Portfolio

More than 15 years of global industry experience in molecular testing and NGS▪ System, Product, and Assay Launch▪ Wet bench and Bioinformatic Experienced▪ SEAM Management Certified▪ VOC, KOL and Market Development ▪ Focus Groups/Advisory Board Leader▪ Significant Biomarker and Content Expertise

More than 15 years of clinical diagnostics experience ▪ Assay development, validation, & commercialization▪ High-Complexity Molecular Testing▪ Emerging Technology Market Assessment▪ Implementation of New Technologies in Clinical Diagnostics▪ Clinical Trials for Pharma and Device Manufacturers▪ Genomics program development and pipeline strategies▪ Strategic development and M & A’s

Jamie Platt, PhD, MB(ASCP)CEO/Founder

Shawn Clairmont, MBAChief Operating Officer

Martin Siaw, PhD, MB(ASCP)VP of Science & Innovation

Invited Speakers at the Liquid Biopsy Summit,NextGen Dx Summit, Molecular Medicine TriConference….

Consulting & Partnering Services

Market Strategy and Development

Portfolio Pipeline

Development

Genomics

Next Generation SequencingTechnology

Emerging Technology

Development

LDT Development Process

Locum Tenens Staffing and Recruiting

Focus Group &

Advisory Board

Informatics

Processes Pay Off

The Assay Commercialization Process

Examples of Completed Projects

Global Business Development

Build out (de novo)Transition (low- to high-complexity)

Assay Pipeline Strategy DevelopmentValidation Guidance

NGS Technical ExpertiseWorkflow and Automation

Customization

RegulatoryCAP accreditationCLIA certification

NYS CLEPISO 15189ISO 13485

California DFSCOLA

Pharma + Service ProviderDevice Co. + Technology Co.

Lab + Tools ProviderService Provider + Software Co.

Lab + Lab

Strategic MarketingMarket AssessmentContent Marketing

Focus GroupsAdvisory Boards

White Papers

LaboratorySales and Marketing

More than Information… SolutionsWe’d love to connect with you!

info@BRIDGenomics.com949-244-2591